Cargando…

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?

Detalles Bibliográficos
Autores principales:	Wahren, B, Engström, G, Aperia, K, Gudmundsdotter, L, Sandström, E, Albert, J, Bråve, A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716887/ http://dx.doi.org/10.1186/1742-4690-3-S1-P64

Ejemplares similares

P19-29. Determining the optimal protocol for plasmid DNA vaccine delivery by intradermal in vivo electroporation
por: Hallengärd, D, et al.
Publicado: (2009)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation
por: Bråve, Andreas, et al.
Publicado: (2010)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
por: Bakari, M, et al.
Publicado: (2009)

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Immunotherapy with an HIV-DNA Vaccine in Children and Adults
por: Palma, Paolo, et al.
Publicado: (2014)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Yeast surface display of HIV Env protein variants for the discovery of novel vaccine immunogens
por: Grimm, S, et al.
Publicado: (2012)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors
por: Zhang, X, et al.
Publicado: (2012)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
por: Zhang, C, et al.
Publicado: (2009)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
por: Tung, F, et al.
Publicado: (2012)

P19-01. Pre-clinical immunogenicity of mosaic Asian AE/B HIV-1 DNA vaccine in mice
por: Sirivichayakul, S, et al.
Publicado: (2009)

A minimal T-cell immunogen designed to cover HIV-1 specificities associated with control is immunogenic in mice and breaks CTL immunodominance
por: Mothe, B, et al.
Publicado: (2012)

Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of immunological memory and long-term toxicology
por: Bråve, Andreas, et al.
Publicado: (2007)

Oral delivery of transgenic plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to higher doses
por: Lindh, I, et al.
Publicado: (2012)

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial
por: Nilsson, Charlotta, et al.
Publicado: (2015)

Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients
por: Lagler, H, et al.
Publicado: (2010)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
por: Borthwick, NJ, et al.
Publicado: (2012)

P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers
por: Aboud, S, et al.
Publicado: (2009)

Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens
por: Chiu, Y, et al.
Publicado: (2012)

P19-07. Development of a protective HIV/SIV vaccine based on a self-boosting cytomegalovirus vector
por: Ambagala, A, et al.
Publicado: (2009)

P12-01. Construction and characterization of recombinant envelope glycoproteins derived from HIV-1 pre-seroconversion strains as potential vaccine immunogens
por: Reddy, S Mohana Rama, et al.
Publicado: (2009)

P19-44. Priming with a DNA vaccine enconding HIV CD4+ T cell epitopes enhances responses against subsequent immunization with plasmid encoding Vif
por: Ribeiro, SP, et al.
Publicado: (2009)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Immunogenicity of a lambda phage-based anti-cancer vaccine targeting HAAH
por: Fuller, Steven, et al.
Publicado: (2013)

Receptor Binding by Cholera Toxin B-Subunit and Amino Acid Modification Improves Minimal Peptide Immunogenicity
por: Boberg, Andreas, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l7e2en47g4h849koao6on0njbl